Skip to main content

Utdanning

  • Lege (MD) ved det medisinske fakultet, Universitet i Oslo (2012)
  • Doktorgrad ved det medisinske fakultet, Universitetet i Oslo (2019)

Stilling

  • Post.doc. i revmatologi, Diakonhjemmet sykehus
  • Lege i spesialisering, revmatologi/indremedisin, Diakonhjemmet Sykehus

Interessefelt

  • Inflammatoriske leddsykdommer
  • Revmatoid artritt
  • Ekstra-artikulære manifestasjoner ved revmatoid artritt
  • Interstitiell lungesykdom ved revmatoid artritt
  • Ultralyd
  • Leddinjeksjoner

Annet

  • I arrangørkomiteen for Grønn kongress

E-post

Denne e-postadressen er beskyttet mot programmer som samler e-postadresser. Du må aktivere javaskript for å kunne se den.

Telefon

Besøksadresse

Diakonhjemmet sykehus
Forstanderboligen
Reidar Kobros vei 8
0370 Oslo

Postadresse

Diakohjemmet sykehus
Postboks 23 Vinderen
0319 Oslo

Prosjekter

WP1 - Behandlingsstudier

ARCTIC

Remisjon hos pasienter med revmatoid artritt: en randomisert kontrollert studie som undersøker bruk av ultralyd i klinisk oppfølging

WP1 - Behandlingsstudier

ARCTIC FORWARD

10-års oppfølging av pasienter med revmatoid artritt som mottok strukturert behandling-til-mål-terapi i tidlig sykdomsfase.

WP4 - Håndtering av tilleggssykdommer

DiettStudien

I en stor randomisert internasjonal studie vil vi vurdere om 4-minutterskort informasjon om hjertevennlig kosthold har samme effekt som individuelt tilpasset 60-minutters kostveiledning.


Publikasjoner

Publikasjoner hentet fra Nasjonalt vitenarkiv (NVA):

Successful discontinuation of oral glucocorticoids after short-term bridging therapy in patients with newly diagnosed rheumatoid arthritis

2026

Study protocol for the PICASSO trial: A randomized placebo-controlled trial to investigate the efficacy and safety of intraarticular steroid injections and an occupational therapy intervention in painful inflammatory carpometacarpal-1 osteoarthritis

2025

How to score the wrist joint by ultrasound: exploration of the most sensitive joint assessment during follow-up of early or established rheumatoid arthritis

2025

Performance of the Rheumatoid Arthritis Impact of Disease (RAID) score in relation to flares in disease activity

2024

Agreement between patient-reported flares and clinically significant flare status in patients with rheumatoid arthritis in sustained remission: data from the ARCTIC REWIND trials

2024

Cooperation across healthcare service levels for medication reviews in older people with polypharmacy admitted to a municipal in-patient acute care unit (The COOP II Study): study protocol for a randomized controlled trial

2024

High viral loads combined with inflammatory markers predict disease severity in hospitalized COVID-19 patients: Results from the NOR-Solidarity trial

2024

Rheumatology congresses post COVID-19: we cannot regress

2023

Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment

2021

Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-To-Target strategy

2021

Conventional versus ultrasound treat to target: No difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis

2020

Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial

2018

The impact of ultrasound on the use and efficacy of intraarticular glucocorticoid injections in early rheumatoid arthritis: Secondary analyses from a randomized trial examining the benefit of ultrasound in a clinical tight control regimen

2018

Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria

2017

Ultrasound in management of rheumatoid arthritis: ARCTIC randomised controlled strategy trial

2016